Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study.

Eur J Haematol · 2025 · PMC11707817 · PMID 39434416

Europe PMC DOI

hedged sentence

0.4354

closest p · 8.7× alpha

0.4354

boldest claim

The sentences

did not reach statistical significancep = 0.4354not close (p > 0.1)

The mean (SD) reduction in ABR of −0.8 (5.2) and annualized factor consumption (IU) of −38 116 (102 283) did not reach statistical significance ( p = 0.4354 and p = 0.2001, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.